Voyager Therapeutics
(NASDAQ) VYGR
Voyager Therapeutics Financials at a Glance
Market Cap
$207.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$36.49M
Net Income (TTM)
-$116.64M
EPS (TTM)
-$1.98
P/E Ratio
-1.74
Dividend
$0.00
Beta (Volatility)
1.36 (Average)
Dividend
$0.00
Beta (Volatility)
1.36 (Average)
Price
$3.46
Volume
23,253
Open
$3.62
Price
$3.46
Volume
23,253
Open
$3.62
Previous Close
$3.46
Daily Range
$3.42 - $3.62
52-Week Range
$2.88 - $5.55
Estimated Earnings Date
Aug 5, 2026
Dividend
$0.00
Beta (Volatility)
1.36 (Average)
Price
$3.46
Volume
23,253
Open
$3.62
Previous Close
$3.46
Daily Range
$3.42 - $3.62
52-Week Range
$2.88 - $5.55
Estimated Earnings Date
Aug 5, 2026
VYGR News
VYGR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Voyager Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
141
CEO
Alfred W. Sandrock, Jr., MD
Website
www.voyagertherapeutics.comHeadquarters
Lexington, MA 02139, US
VYGR Financials
Key Financial Metrics (TTM)
Gross Margin
-178.62%
Operating Margin
-349.16%
Net Income Margin
-319.61%
Return on Equity
-55.97%
Return on Capital
-56.69%
Return on Assets
-53.18%
Earnings Yield
-57.47%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$207.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
60.42M
Volume
23.25K
Avg. Volume
595.06K
Financials (TTM)
Gross Profit
-$65.19M
Operating Income
-$127.42M
EBITDA
-$112.54M
Operating Cash Flow
-$127.99M
Capital Expenditure
-$1.95M
Free Cash Flow
-$129.94M
Cash & ST Invst.
$141.48M
Total Debt
$34.57M
Voyager Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.59M
-59.9%
Gross Profit
$1.66M
+106.6%
Gross Margin
64.06%
N/A
Market Cap
$207.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$1.21M
N/A
Employees
172
N/A
Net Income
-$27.94M
+9.9%
EBITDA
-$26.99M
+9.9%
Quarterly Fundamentals
Total Cash
$141.48M
-40.1%
Total Debt
$34.57M
-17.7%
Accounts Receivable
$1.65M
-22.0%
Inventory
$0.00
N/A
Long Term Debt
$27.20M
-21.3%
Short Term Debt
$7.36M
-0.9%
Return on Assets
-53.18%
N/A
Return on Invested Capital
-63.12%
N/A
Free Cash Flow
-$33.43M
+13.3%
Operating Cash Flow
-$33.42M
+11.8%